Retrospektywna analiza skuteczno ści nilotynibu i dazatynibu w drugiej linii terapii przewlekłej białaczki szpikowej w polskich ośrodkach hematologicznych

In conclusion, the results of our analysis indicate that nilotinib and dasatinib have comparable and satisfactory efficacy in the treatment of CML patients refractory or intolerant to imatinib. Our findings support current strategy of choice of IKT-2G according to drug toxicity profile and risk of specific adverse events in an individual patient.
Source: Acta Haematologica Polonica - Category: Hematology Source Type: research